Abecma (idecabtagene vicleucel) for an Omani patient: what the pathway looks like in 2026

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

Multiple myeloma is, for many Omani families, a disease that has been managed in the kingdom and the wider region for years. Diagnosis at Sultan Qaboos University Hospital (SQUH) or Royal Hospital Muscat. Induction with bortezomib, lenalidomide, and dexamethasone. Maintenance lenalidomide. Eventually a relapse, often a second relapse, and a conversation about what comes after daratumumab-based regimens have been exhausted. That conversation, in 2026, increasingly includes BCMA-directed CAR-T cell therapy. Abecma is the first FDA-approved BCMA CAR-T for multiple myeloma. For an Omani patient considering it, the operational reality is that Oman does not yet have an in-country certified cell therapy centre administering commercial Abecma, and the practical pathway is cross-border to King Faisal Specialist Hospital and Research Centre in Riyadh, the certified cell therapy programmes operating in Abu Dhabi (Cleveland Clinic Abu Dhabi, Sheikh Shakhbout Medical City (SSMC), and Tawam Hospital Al Ain), the National Center for Cancer Care and Research at Hamad Medical Corporation in Doha, King Hussein Cancer Center in Amman, or the wider international Authorized Treatment Center network. Sidra Medicine in Doha is the paediatric gene therapy reference centre and is not the relevant centre for adult multiple myeloma.

This page is meant to be the first honest read you get on Abecma for a Oman-based patient, written by the team that would coordinate around your case if you decided to go forward. We assume your treating haematologist has raised this with you, or you have raised it with them.

We will be specific about who Abecma is approved for, where it can be administered for an Omani-based patient, what the workup decides, the cost in OMR and US dollars, how the DGPADC and cross-border pathways work, what insurance and MoH treatment-abroad funding may or may not cover, what the four-week post-infusion restricted period demands operationally, and what life looks like in the year after treatment.

What Abecma actually is, in plain terms

Abecma is an autologous BCMA-directed CAR-T cell therapy. The mechanism, told the way a family needs to understand it, is that the patient's own T cells (white blood cells that fight disease) are collected from blood through an apheresis session, shipped to Bristol Myers Squibb's manufacturing facility, genetically engineered to express a chimeric antigen receptor that recognises B-cell maturation antigen (BCMA) on the surface of myeloma plasma cells, and returned. After a short course of lymphodepleting chemotherapy that creates space for the engineered cells to expand, the manufactured CAR-T product is infused once.

The cells then expand inside the body, recognise BCMA on myeloma cells, and kill them. The response is durable in a meaningful proportion of patients. In the KarMMa-3 Phase 3 randomised trial, median progression-free survival was 13.3 months on Abecma versus 4.4 months on standard combination regimens, and the overall response rate was 71 percent versus 42 percent.

Abecma is not a chronic medication. It is a one-time cell therapy. The treatment arc, from leukapheresis to the end of the post-infusion restricted period, is approximately three to four months. The follow-up is then standard haematology surveillance for cytopenias, infections, and second-primary malignancies for fifteen years per FDA REMS requirements.

What Abecma is not is an outpatient infusion in the way that a daratumumab dose is. The patient is admitted for monitoring after the infusion, typically for seven to fourteen days, because the two main acute toxicities (cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome) need to be recognised and managed in real time by a trained cell therapy team.

Who is currently a candidate, and who is not

The FDA-approved indication, as expanded in 2024, is adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent (lenalidomide or pomalidomide), a proteasome inhibitor (bortezomib or carfilzomib), and an anti-CD38 monoclonal antibody (daratumumab or isatuximab). The patient must have been refractory to or relapsed on the last regimen.

For most Omani patients arriving at this conversation, the prior-line floor is met. Standard MoH and private-sector practice in Oman has aligned with international guidelines that anchor first-line on a daratumumab-bortezomib-lenalidomide-dexamethasone quadruplet, with later lines built on pomalidomide, carfilzomib, and isatuximab.

Beyond prior-line exposure, the eligibility threshold is performance status (typically ECOG 0 or 1, with ECOG 2 considered case by case), adequate cardiac and pulmonary function for the lymphodepleting chemotherapy, no active CNS involvement of myeloma, and no active uncontrolled infection.

If you are early in your disease course, with only one prior line, the case for Abecma now is harder than the case for one of the BCMA-directed bispecific antibodies that are off-the-shelf and do not require a manufacturing wait. We will be honest about that comparison. If you are deep into the disease, with rapid progression on the most recent regimen, the manufacturing wait of four to five weeks becomes its own constraint, and the bridging-therapy plan to control disease during that window matters more than usual.

The DGPADC pathway and cross-border coordination

Oman's Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) has had a formal advanced therapy medicinal products framework since 2019, including the Gene Therapy Products Registration and Control Regulations. The regulatory framework is mature and the named-patient mechanism is available for unregistered specialty therapies o